GOVERNMENT BUSINESS

Treasury Board Secretariat on behalf of Ontario Ministry of Finance Awards Key Mission-Critical

Fairfax Software | January 17, 2022

Fairfax Software is pleased to announce that it has been recently awarded a contract by the Ontario Government to provide: comprehensive software solution for payment processing (electronic and paper-based), image processing of paper for non-remittance forms, and full-service data entry. This contract was awarded to Fairfax Software following rigorous competitive procurement undertaken by the Treasury Board Secretariat on behalf of Ministry of Finance (MOF). Fairfax Software will implement and integrate the latest version of its Quick Modules 5.0 software suite, which provides a single platform designed to process all of MOF's 5.9 million annual inbound mail and electronic transactions for payment processing and data capture.

This comprehensive solution will support all 126 business programs across 16 client ministries and will include technical and operational training. Fairfax Software's extensive solution will also cover and support approximately 90 new and existing interface files with 15 separate systems. The contract calls for design and implementation over eighteen-month period, a phased rollout of twenty-four months, and a full operation period of three and half years but has the potential for a 15-year term.

Fairfax Software's solution is unique by providing an efficient approach with a streamlined single platform of imaging, remittance processing, data capture, monitoring, and reporting for all payment types while balancing, reconciling, and depositing the daily fund receipts. Many technical features and business benefits associated with the implementation of the Quick Modules 5.0 system have solidified Fairfax Software as an industry leader.

The Fairfax Software award-winning solution Quick Modules 5.0 was built from the ground up to process real-life payment data and electronic transactions, along with all its associated attachments, with or without remittance, all in one single workflow under one common Microsoft (NASDAQ: MSFT) SQL Server database. This paradigm, which was invented and commercialized by Fairfax Software, has become a staple in U.S.-based state and commercial payment front-end processing for the last decade or more. More U.S. state tax and revenue agencies have adopted this paradigm than not.

"We are delighted to have earned this contract and honored to serve the Ontario Government. Our single platform solution will streamline the Ministry's workflow in the most efficient way possible and in an enterprise-wide capacity." Michael Minter, Vice President of Sales and Marketing stated: "Our award-winning Quick Modules solution has met and exceeded the competitive scrutiny of the Ontario Government's procurement process. Once again, we have proven that our solution is the best on the market for processing incoming mission-critical data."

Steve Chahal, President and Chief Executive Officer of Fairfax Software

Fairfax Software has been providing state-of-the-art data capture and remittance processing solutions to state government clients, and more specifically state revenue clients since 1994 and with this award extends its solution footprint abroad. Fairfax Software's solutions, based on the signature product Quick Modules, are now the de-facto engine powering the payment and data capture processes in thirty-three (33) different U.S. states and forty-three (43) state agencies. Fairfax Software is capitalizing on its success in the United States' marketplace and expanding its award-winning software into the Canadian market.

Fairfax Software has recently announced that it is henceforth offering to host its mission-critical state government solutions in its secure and encrypted cloud on Amazon (NASDAQ: AMZN) Web Services (AWS) and Microsoft Azure with several state governments having adopted it.

Spotlight

In the majority of cases, the consequences are mostly economic — trade barriers are enacted, and then retaliatory measures are used to counter. Relations can continue to escalate until an understanding can be reached by both parties.


Other News
GOVERNMENT BUSINESS

Securing the New Digital Ecosystem: Resecurity® Exhibits at DoDIIS 2021

Resecurity | December 17, 2021

Resecurity®, a cybersecurity and intelligence company, today announced the unveiling of their next-generation cybersecurity platform at the 2021 Department of Defense Intelligence Information System (DoDIIS) Worldwide Conference in Pheonix, Arizona. For nearly 20 years, the DoDIIS Worldwide Conference has served as the premier information technology conference welcoming over 2,000 attendees and representing over 400 different government organizations. Government organizations face an uncharted digital ecosystem that has led to record cyber incidents and advanced adversarial tactics in 2021. This year's conference theme, Foresight 20/20: Building a New Digital Ecosystem, emphasized the need to adopt innovative solutions and collaborate across the industry to maintain a competitive strategic advantage over adversaries. "We simply can't count on hope and good luck to save us from strategic surprise, specifically in the cyber domain in which we operate. We need the strongest possible national unity and purpose to protect our Nation's secrets and keep pace with our adversaries." Michael Waschull, acting Intelligence Community chief information officer and deputy IC CIO, during a keynote session Uniquely positioned to provide ecosystem protection and real-time threat intelligence, Resecurity exhibited their latest research, risk management and security capabilities that protect organizations on multiple levels, including network, cloud, applications and users. Particularly relevant for the government sector, they shared risk intelligence innovations designed to identify and score the network, identity, technology, and geographical risks within an organization's security ecosystem. "Resecurity is proud to have participated in this year's DoDIIS conference. As government organizations look to secure their growing ecosystems, we must come together to collaborate, solve challenges, and share best practices," said Gene Yoo, CEO of Resecurity. "Solutions like Resecurity's cyber risk and intelligence platform are essential to compete with adversaries in the new digital ecosystem, providing security leaders increased visibility and actionable data to protect their organizations." About Resecurity Resecurity® is a cybersecurity company that delivers a unified platform for endpoint protection, risk management, and cyber threat intelligence. Known for providing best-of-breed data-driven intelligence solutions, Resecurity's services and platforms focus on early-warning identification of data breaches and comprehensive protection against cybersecurity risks. Founded in 2016, it has been globally recognized as one of the world's most innovative cybersecurity companies with the sole mission of enabling organizations to combat cyber threats regardless of how sophisticated they are. Most recently, Resecurity was named one of the Top 10 fastest-growing private cybersecurity companies in Los Angeles, California by Inc. Magazine.

Read More

EMERGING TECHNOLOGY

Edge AI and Vision Alliance Announces 2022 Edge AI and Vision Product of the Year Award Winners

Edge AI and Vision Alliance | May 18, 2022

The Edge AI and Vision Alliance announced the 2022 winners of the Edge AI and Vision Product of the Year Awards. The Awards celebrate the innovation and achievement of the industry's leading companies that are enabling and developing products incorporating edge AI and computer vision technologies. This is the fifth year of our awards program and once again we were impressed with the number of high-quality entries across a broad range of product categories—from building-block technologies to ready-to-use solutions delivered directly to consumers and enterprises. The popularity of our awards program is a testament to the diversity and accelerating expansion of edge AI and vision technologies into virtually every industry." Jeff Bier, Founder of the Edge AI and Vision Alliance Entries are judged by an independent, expert panel on innovation, impact on customers and the market, and competitive differentiation. The winners and their reactions to their awards include: Best Edge AI Processor: Blaize—Pathfinder P1600 Embedded System on Module "Blaize is honored that the Edge AI and Vision Alliance's panel of independent industry judges selected our Blaize Pathfinder P1600 Embedded SoM as the Best Edge AI Processor in the 2022 Edge AI and Vision Product of the Year Awards. Our chip is a software-defined AI inference accelerator based on the Blaize Graph Streaming Processor (GSP) architecture with low power, low latency, and energy efficiency ideal for AI inferencing workloads at the Edge," said Dinakar Munagala, Co-founder and CEO, Blaize. Honorable Mention, Edge AI Processor: CEVA—NuePro-M This year the judges issued their first Honorable Mention for a Product of the Year Award in the Edge AI Processor category to recognize CEVA for its NuePro-M product. The independent panel of judges evaluated CEVA's entry on innovation, differentiation, market impact and customer impact. CEVA's entry received an impressive score and the judges recommended that CEVA receive this special recognition. Best Camera or Sensor: Luxonis—OAK-D-Lite "Our goal when we started Luxonis was to make Robotics Perception Easy. Our users have discovered that with OAK devices, they can just get to work solving their robotics problems— instead of fighting to integrate disparate hardware, firmware and software." said Brandon Gilles, CEO at Luxonis. "Luxonis has accomplished this with our OAK devices, which include the OAK-D-LITE, the 2022 Edge AI and Vision Product of the Year award winner in the Camera or Sensor category." Best Edge AI Software or Algorithm: Sequitur Labs—EmSPARK Security Site 3.0 "Edge AI is amazing… but only if it's secure. Sequitur Labs continues to lead the way in protecting AI models at the edge," said Phil Attfield, CEO at Sequitur Labs. "It's an honor to be recognized by the Edge AI and Vision Alliance. Thanks for the award!" Best Edge AI Developer Tool: Edge Impulse—EON Compiler "On behalf of the Edge Impulse team, we're honored to receive this year's Edge AI and Vision Product Award in the Edge AI Developer Tools category. We believe the EON Tuner represents a major breakthrough in the world of edge machine learning, by enabling you to find and select the best model for your application within the constraints of your target device in just a few clicks," said Jan Jongboom, Edge Impulse Co-Founder and CTO. "This provides developers and enterprises the confidence they need to build the optimal ML pipeline for their real-world vision solution." Best Automotive Solution: Synopsys—DesignWare ARC EV7xFS Processor IP for Functional Safety "We thank the Edge AI and Vision Alliance for recognizing the Synopsys ARC EV7xFS Processor IP with the 'Best Automotive AI Product of 2022' award. The Synopsys ARC EV7xFS processor family, the recently announced Synopsys ARC NPX6FS processor family, and Synopsys' comprehensive solution for automotive designs enable companies to create differentiated, safe, and secure SoCs while accelerating time to market," said John Koeter, Sr. Vice President of Marketing and Strategy for IP at Synopsys. Best Enterprise Edge AI End Product: Grabango—Grabango's Checkout-Free Technology "Grabango is honored to be recognized as a 2022 Edge AI and Vision Product of the Year winner." said Will Glaser, founder and CEO of Grabango. "Powered by advanced computer vision technology, Grabango's checkout-free solution offers a differentiated, technical approach to a seemingly simple problem—eliminating lines and saving shoppers time." Best Consumer Edge AI End Product: OrCam Technologies—OrCam Read OrCam Read is the first of a new class of easy-to-use handheld digital readers that supports people with mild to moderate vision loss, as well as those with reading challenges, to access the texts they need and to more effectively accomplish their daily tasks. All of OrCam Read's information processing—from its text-to-speech functionality implemented to operate on the edge, to its voice-controlled operation using the "Hey OrCam" voice assistant, to the natural language processing and natural language understanding-driven Smart Reading feature—is processed locally, on the device, with no data connectivity required. About the Edge AI and Vision Alliance The Edge AI and Vision Alliance is a worldwide industry partnership bringing together technology providers and end-product companies who are creating and enabling innovative and practical applications for computer vision and edge AI. Membership is open to any company that supplies or uses technology for edge AI and vision systems and applications.

Read More

GOVERNMENT FINANCE

Xlear Files Legal Response to Government’s Lawsuit

Xlear | December 23, 2021

Today, Xlear Inc. filed the company’s response to a Department of Justice lawsuit alleging violations of the Federal Trade Commission Act, among other allegations. The company denied all the Government’s allegations and leveled a series of affirmative defenses at the Government, including violations of Xlear’s First Amendment right to free speech. Nathan Jones, Xlear’s CEO, issued this statement regarding Xlear’s Response: The United States faces an already raging pandemic and yet another new, wildfire Omicron variant, which studies show is more transmissible, vaccine resistant and as severe as other strains. As a result, across the nation new cases are spiking and breaking records; hospitals are once again overflowing; schools are closing again; not only are we seeing breakthrough infections—we are facing reinfections; the NFL and the NHL have been forced to postpone games; and, there is a real risk that our lives and economy will once again have to close. It’s another COVID-Christmas in America. The nation’s vaccine-only strategy is failing. Despite this, the Federal Government continues to refuse to even discuss or consider other possible countermeasures—even though they are backed by sound science. Xlear’s Response outlines a series of studies, including two randomized clinical trials (RCTs)* and other clinical and lab data, that more than substantiate Xlear’s statements regarding COVID-19. One recent RCT study found that the use of nasal hygiene in treating COVID-19-infected people over the age of 50 reduced the risk of hospitalization 8-fold.** The Government hasn’t meaningfully challenged the legitimacy of these studies—the Government can’t, they paid for some of them and have published some of them. Nor has the Government offered conflicting studies—they can’t. The Government has known about these other countermeasures since June 2020. Yet, the Government still refuses to even discuss or consider them. The Response we filed also includes a new in vitro study done at Utah State University’s Institute for Antiviral Research.*** This new in vitro study (using human airway tissue) found that the components in Xlear were significantly more effective antivirals against the Delta strain of COVID-19 than Remdesivir, the Government-approved antiviral medicine. Ironically, the Government alleges it is Xlear that has misled the public. Not only is the Government refusing to consider other countermeasures, the Government, through this lawsuit, has sought to censor us from informing the American people about the science. The American people have both the right and the need to know the science. We hope this lawsuit serves as a vehicle to inform the public, as well as expose the abject failures of our Government in responding to this pandemic.

Read More

GOVERNMENT BUSINESS

Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir

Merck | December 22, 2021

Merck , known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the United Kingdom Government will purchase an additional 1.75 million patient courses of molnupiravir (MK-4482), an investigational oral antiviral COVID-19 medicine. In the U.K., LAGEVRIO® is the planned trademark for molnupiravir; the trademark for molnupiravir in other countries has not been approved. With this additional procurement agreement, which follows a previously announced agreement for 480,000 courses of treatment, the U.K. Government has now committed to purchase a total of 2.23 million courses of molnupiravir. In early November, molnupiravir received conditional marketing authorization in the U.K. for the treatment of mild to moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness. Molnupiravir is currently available in the U.K. and patients have started to receive treatment. An application for Emergency Use Authorization for molnupiravir is under review by the U.S. Food and Drug Administration. Merck has entered into advance purchase and supply agreements for molnupiravir with governments of more than 30 countries worldwide, including 21 agreements with countries in Europe. About Merck’s Global Efforts to Accelerate Access to Molnupiravir Following Regulatory Authorizations or Approvals Global access has been a priority for Merck and Ridgeback since the inception of their molnupiravir collaboration. The companies are committed to providing timely access to molnupiravir globally through our comprehensive supply and access approach, which includes investing at risk to produce millions of courses of therapy; tiered pricing based on the ability of governments to finance health care; entering into supply agreements with governments; and granting voluntary licenses to generic manufacturers and to the Medicines Patent Pool to make generic molnupiravir available in more than 100 low- and middle-income countries following local regulatory authorizations or approvals. Supply: In anticipation of the results from MOVe-OUT and the potential for regulatory authorization or approval, Merck has been producing molnupiravir at risk and expects to produce 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022. To date, Merck has shipped molnupiravir to 12 countries; in countries where it is approved or authorized, patients have begun to receive the drug. Supply agreements: Merck entered into a procurement agreement with the U.S. Government under which the company will supply approximately 3.1 million courses of molnupiravir to the U.S. Government, upon Emergency Use Authorization or approval from the U.S. Food and Drug Administration. Merck has entered into advance purchase and supply agreements for molnupiravir with governments for over 30 countries worldwide, including Australia, Canada, Korea, Japan, Thailand, United Kingdom and United States, pending regulatory authorizations, and is currently in discussions with additional governments. Merck plans to implement a tiered pricing approach based on World Bank country income criteria to reflect countries’ relative ability to finance their health response to the pandemic. Voluntary licenses: As part of its commitment to widespread global access, Merck previously announced that it has entered into a licensing agreement with the Medicines Patent Pool to increase broad access for molnupiravir in low- and middle-income countries. Additionally, Merck previously announced that the company has entered into non-exclusive voluntary licensing agreements for molnupiravir with established generic manufacturers to accelerate availability of molnupiravir in more than 100 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies. Merck continues to discuss additional measures and collaborations to accelerate broad, global access to molnupiravir. About Molnupiravir Molnupiravir (MK-4482) is an investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been shown to be active in several preclinical models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission. Pre-clinical data suggest that molnupiravir has a high barrier to the development of resistance.

Read More

Spotlight

In the majority of cases, the consequences are mostly economic — trade barriers are enacted, and then retaliatory measures are used to counter. Relations can continue to escalate until an understanding can be reached by both parties.

Resources